Abstract: Disclosed are various embodiments for facilitating item bundles. An item bundle includes more than one item from an item universe that can be bundled together. For example, in an electronic marketplace, two items can be linked together as a bundle that is sold. An order document can be created that includes a reference to the item bundle that is associated with an entry for each of the items in the bundle.

Abstract: An event driven computing system generates selected benefit packages that include benefits that are drawn from multiple marketplace platforms and diverse product categories while also protecting consumer information. The event driven computing system may include one or more list generation engines that are each built to generate curated lists of benefits associated with one or more corresponding benefit package programs. The event driven system may then pass the curated lists and an identifier associated with a recipient of the benefit package to a secure customization engine that personalizes the curated sets of benefits to individual consumers based on consumer data. The event driven system can then use the personalized sets of benefits to select benefits for inclusion in the benefit package that are individually tailored to the recipient.

Abstract: The present invention provides a method for determining P1/P2 blood type, including steps of providing a biological sample of a subject, detecting a genotype for single nucleotide polymorphism rs2143918 or rs5751348 in A4GALT gene of the biological sample and determining a phenotype of the subject based on the genotype. Further, the present invention also provides a kit for determining P1/P2 blood type, including a primer pair for detecting a genotype for single nucleotide polymorphisms rs2143918 or rs5751348 in A4GALT gene of a nucleic acid sample of a subject.

Abstract: The present invention provides a method for determining P1/P2 blood type, including steps of providing a biological sample of a subject, detecting a genotype for single nucleotide polymorphism rs2143918 or rs5751348 in A4GALT gene of the biological sample and determining a phenotype of the subject based on the genotype. Further, the present invention also provides a kit for determining P1/P2 blood type, including a primer pair for detecting a genotype for single nucleotide polymorphisms rs2143918 or rs5751348 in A4GALT gene of a nucleic acid sample of a subject.

Abstract: Disclosed are various embodiments for navigating an electronic item database by way of a user intention. A user interface is generated that presents a first result set of items from an electronic item database. The user interface includes one or more user interface components configured to elicit a user selection from multiple user intentions. A particular user intention is determined, then a set of refinement attributes corresponding to the particular user intention is identified. An updated result set of items that matches the set of refinement attributes is determined. The user interface is then updated to present the updated result set of items in place of the result set of items.

Abstract: The present invention provides a method for determining P1/P2 blood type, including steps of providing a biological sample of a subject, detecting a genotype for single nucleotide polymorphism rs2143918 or rs5751348 in A4GALT gene of the biological sample and determining a phenotype of the subject based on the genotype. Further, the present invention also provides a kit for determining P1/P2 blood type, including a primer pair for detecting a genotype for single nucleotide polymorphisms rs2143918 or rs5751348 in A4GALT gene of a nucleic acid sample of a subject.

Abstract: Methods and kits are provided for the simultaneous detection of multiple analytes, i.e. to the determination of whether one or more of a plurality of analytes is present in a sample, particularly the plurality of analytes are structurally unrelated or significantly different, particularly to whether one or more of such analytes is present in a sample in a concentration that is above a predetermined minimum or cutoff value, and particularly for such analytes with different cutoffs. The methods and kits are particularly useful for-screening for the presence of a plurality of drugs (licit and/or illicit), performance-enhancing substances, and other chemicals, and involve a competitive enzyme immunoassay employing one or more conjugates of G6PDH with a plurality of the analytes.

Abstract: This invention provides two novel vectors, a vector comprising a rAAV-type 2 plasmid encoding mutant survivin (Cys84Ala), and a vector comprising a rAAV-type 2 plasmid encoding eGFP. This invention also provides compositions comprising the above vectors. This invention provides a method for inducing apoptosis in a cell comprising introducing into the cell the vector comprising a rAAV-type 2 plasmid encoding mutant survivin (Cys84Ala), or a composition thereof. This invention further provides a method for inhibiting tumor cell growth comprising introducing into the tumor cell the vector comprising a rAAV-type 2 plasmid encoding mutant survivin (Cys84Ala), or a composition thereof. Finally, this invention provides a method of treating a subject having colon cancer comprising administering to the subject a suitable amount of the vector comprising a rAAV-type 2 plasmid encoding mutant survivin (Cys84Ala) in a composition.

Abstract: The invention provides a vector comprising an AAV-shRNA vector. The vector is preferably rAAV-151i/1694i. The invention also provides a method of suppressing or inhibiting HBV replication in liver cells infected therewith, comprising administering an amount of an AAVB-shRNA vector effective to suppress, inhibit or reduce HBV replication.

Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.

Abstract: The present invention discloses methods and kits for retrieving a cannabinoid from an oral fluid collection device having adsorbed the cannabinoid and to prepare an oral fluid specimen for the determination of ?9-tetrahydrocaninabinol (?9-THC) concentration qualitatively or quantitatively by an enzyme immunoassay. The methods and kits are particularly useful in preserving the ?9-THC quantitatively from oral fluid samples during the process of collection and preparation.

Abstract: The present invention discloses homogeneous enzyme immunoassay systems, methods and kits useful for the qualitatively and quantitatively determination of analytes in oral fluid samples. The system involves a competitive enzyme immunoassay employing a conjugate comprising glucose-6-phosphate dehydrogenase (G6PDH) and an analyte. The methods and kits are particularly useful in the detection of recent drug use and for fast determination of analytes using auto-analyzers.

Abstract: A Xenopus laevis (the African clawed frog) embryo model is provided to study the effects of alcohol on fetal development. Exposure of Xenopus embryos in specific developmental stages to alcohol results in tadpoles with microencephaly and growth retardation, in a dose- and time-dependent manner, similar to those observed in human fetal alcohol syndrome (FAS). The invention further provides methods for screening an agent to determine its usefulness for preventing or treating FAS. Moreover, the invention provides methods for preventing or treating FAS in an animal by administering an agent, such an agent includes vitamin C and a catalase, which causes or enhances an expression of Pax6 that is a neural and eye marker. In addition, the invention provides methods for preventing or treating FAS by administering an agent, such as vitamin C, which causes suppression of NF-?B activation.

Abstract: The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.

Abstract: Methods and kits are provided for the simultaneous detection of multiple analytes, i.e. to the determination of whether one or more of a plurality of analytes is present in a sample, particularly the plurality of analytes are structurally unrelated or significantly different, particularly to whether one or more of such analytes is present in a sample in a concentration that is above a predetermined minimum or cutoff value, and particularly for such analytes with different cutoffs. The methods and kits are particularly useful for-screening for the presence of a plurality of drugs (licit and/or illicit), performance-enhancing substances, and other chemicals, and involve a competitive enzyme immunoassay employing one or more conjugates of G6PDH with a plurality of the analytes.